• Acinetobacter baumannii is a bacteria which can become a virulent killer in health-care settings among severely ill patients. • The germ has rapidly developed drug resistance to even last-line carbapenem drugs. • Now a group of Hackensack Meridian Center for Discovery and Innovation (CDI) scientists have found a way to understand how the germ is evolving-and how best to strategize a fight against it.
Article Summaries:
- Scientists at the Hackensack Meridian Center for Discovery and Innovation (CDI) have developed a new approach to track how the drug‑resistant bacterium Acinetobacter baumannii evolves. The pathogen, notorious for causing severe infections in hospitals and rapidly acquiring resistance to last‑line carbapenem antibiotics, poses a growing threat to critically ill patients. CDI researchers used genomic and evolutionary analyses to map resistance pathways, enabling them to identify key genetic changes that drive the bacterium’s survival. Their findings provide a framework for designing targeted therapies and infection‑control strategies, potentially improving outcomes in healthcare settings where A. baumannii outbreaks occur.
Sources: